Teleflex price target raised to $255 from $247 at Truist

Truist analyst Richard Newitter raised the firm’s price target on Teleflex to $255 from $247 and keeps a Hold rating on the shares as part of a broader research note previewing Q3 results for the MedTech sector. While the firm believes that any hurricane related headwind call-outs for Q4 will generally get “a pass” from investors, it could cause companies with elective or deferrable procedure areas to see more muted guide increases, the analyst tells investors in a research note. For the stock, Truist contends that a valuation discount is warranted given its organic revenue and EPS growth, which are more in-line with the lower-end of its peer group. The firm also notes that some more concrete quantification are needed around the timing and magnitude of potential IABP revenue contribution and EPS impact in 2025.